Coronary artery bypass surgery use of ACE Inhibitors/ARBs
Jump to navigation
Jump to search
|
Coronary Artery Bypass Surgery Microchapters | |
|
Pathophysiology | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Perioperative Monitoring | |
|
Surgical Procedure | |
|
Special Scenarios | |
|
Coronary artery bypass surgery use of ACE Inhibitors/ARBs On the Web | |
|
FDA on Coronary artery bypass surgery use of ACE Inhibitors/ARBs | |
|
CDC on Coronary artery bypass surgery use of ACE Inhibitors/ARBs | |
|
Coronary artery bypass surgery use of ACE Inhibitors/ARBs in the news | |
|
Blogs on Coronary artery bypass surgery use of ACE Inhibitors/ARBs|- |
|
|
Directions to Hospitals Performing Coronary artery bypass surgery use of ACE Inhibitors/ARBs | |
|
Risk calculators for Coronary artery bypass surgery use of ACE Inhibitors/ARBs | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Varun Kumar, M.B.B.S. [2]
2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]
Angiotensin-Converting Enzyme Inhibitors and Angiotensin-Receptor Blockers (DO NOT EDIT)[1]
| Class I |
| "1. Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers given before CABG should be reinstituted postoperatively once the patient is stable, unless contraindicated.[2][3][4] (Level of Evidence: B)" |
| "2. ACE inhibitors or angiotensin-receptor blockers should be initiated postoperatively and continued indefinitely in CABG patients who were not receiving them preoperatively, who are stable, and who have an LVEF less than or equal to 40%, hypertension, diabetes mellitus, or chronic kidney disease, unless contraindicated.[2][4][5][6] (Level of Evidence: A)" |
| Class IIa |
| "1. It is reasonable to initiate ACE inhibitors or angiotensin-receptor blockers postoperatively and to continue them indefinitely in all CABG patients who were not receiving them preoperatively and are considered to be at low risk (ie, those with a normal LVEF in whom cardiovascular risk factors are well controlled), unless contraindicated.[2][4][7][8][9] (Level of Evidence: B)" |
| Class IIb |
| "1. The safety of the preoperative administration of ACE inhibitors or angiotensin-receptor blockers in patients on chronic therapy is uncertain.[10][11][12][13][14][15] (Level of Evidence: B)" |
| "2. The safety of initiating ACE inhibitors or angiotensin-receptor blockers before hospital discharge is not well established.[2][7][9][16] (Level of Evidence: B)" |
References
- ↑ 1.0 1.1 Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.
- ↑ 2.0 2.1 2.2 2.3 Goyal A, Alexander JH, Hafley GE, Graham SH, Mehta RH, Mack MJ, Wolf RK, Cohn LH, Kouchoukos NT, Harrington RA, Gennevois D, Gibson CM, Califf RM, Ferguson TB, Peterson ED (2007). "Outcomes associated with the use of secondary prevention medications after coronary artery bypass graft surgery". The Annals of Thoracic Surgery. 83 (3): 993–1001. doi:10.1016/j.athoracsur.2006.10.046. PMID 17307447. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Smith SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, Gibbons RJ, Grundy SM, Hiratzka LF, Jones DW, Lloyd-Jones DM, Minissian M, Mosca L, Peterson ED, Sacco RL, Spertus J, Stein JH, Taubert KA (2011). "AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation". Circulation. 124 (22): 2458–73. doi:10.1161/CIR.0b013e318235eb4d. PMID 22052934. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ 4.0 4.1 4.2 Oosterga M, Voors AA, Pinto YM, Buikema H, Grandjean JG, Kingma JH, Crijns HJ, van Gilst WH (2001). "Effects of quinapril on clinical outcome after coronary artery bypass grafting (The QUO VADIS Study). QUinapril on Vascular Ace and Determinants of Ischemia". The American Journal of Cardiology. 87 (5): 542–6. PMID 11230836. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Garg R, Yusuf S (1995). "Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials". JAMA : the Journal of the American Medical Association. 273 (18): 1450–6. PMID 7654275. Unknown parameter
|month=ignored (help);|access-date=requires|url=(help) - ↑ Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000). "Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators". The New England Journal of Medicine. 342 (3): 145–53. doi:10.1056/NEJM200001203420301. PMID 10639539. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ 7.0 7.1 Fox KM, Bertrand ME, Remme WJ, Ferrari R, Simoons ML, Deckers JW (2007). "Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease". American Heart Journal. 153 (4): 629–35. doi:10.1016/j.ahj.2007.01.032. PMID 17383303. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Kjøller-Hansen L, Steffensen R, Grande P (2000). "The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES)". Journal of the American College of Cardiology. 35 (4): 881–8. PMID 10732883. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ 9.0 9.1 Rouleau JL, Warnica WJ, Baillot R, Block PJ, Chocron S, Johnstone D, Myers MG, Calciu CD, Dalle-Ave S, Martineau P, Mormont C, van Gilst WH (2008). "Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery". Circulation. 117 (1): 24–31. doi:10.1161/CIRCULATIONAHA.106.685073. PMID 18071079. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Arora P, Rajagopalam S, Ranjan R, Kolli H, Singh M, Venuto R, Lohr J (2008). "Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery". Clinical Journal of the American Society of Nephrology : CJASN. 3 (5): 1266–73. doi:10.2215/CJN.05271107. PMC 2518804. PMID 18667735. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Benedetto U, Sciarretta S, Roscitano A, Fiorani B, Refice S, Angeloni E, Sinatra R (2008). "Preoperative Angiotensin-converting enzyme inhibitors and acute kidney injury after coronary artery bypass grafting". The Annals of Thoracic Surgery. 86 (4): 1160–5. doi:10.1016/j.athoracsur.2008.06.018. PMID 18805152. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Levin MA, Lin HM, Castillo JG, Adams DH, Reich DL, Fischer GW (2009). "Early on-cardiopulmonary bypass hypotension and other factors associated with vasoplegic syndrome". Circulation. 120 (17): 1664–71. doi:10.1161/CIRCULATIONAHA.108.814533. PMID 19822810. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Miceli A, Capoun R, Fino C, Narayan P, Bryan AJ, Angelini GD, Caputo M (2009). "Effects of angiotensin-converting enzyme inhibitor therapy on clinical outcome in patients undergoing coronary artery bypass grafting". Journal of the American College of Cardiology. 54 (19): 1778–84. doi:10.1016/j.jacc.2009.07.008. PMID 19682819. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Rader F, Van Wagoner DR, Gillinov AM, Blackstone EH (2010). "Preoperative angiotensin-blocking drug therapy is not associated with atrial fibrillation after cardiac surgery". American Heart Journal. 160 (2): 329–336.e1. doi:10.1016/j.ahj.2010.05.033. PMC 2919305. PMID 20691840. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ White CM, Kluger J, Lertsburapa K, Faheem O, Coleman CI (2007). "Effect of preoperative angiotensin converting enzyme inhibitor or angiotensin receptor blocker use on the frequency of atrial fibrillation after cardiac surgery: a cohort study from the atrial fibrillation suppression trials II and III". European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery. 31 (5): 817–20. doi:10.1016/j.ejcts.2007.02.010. PMID 17350856. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help) - ↑ Eagle KA, Guyton RA, Davidoff R, Edwards FH, Ewy GA, Gardner TJ, Hart JC, Herrmann HC, Hillis LD, Hutter AM, Lytle BW, Marlow RA, Nugent WC, Orszulak TA (2004). "ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery)". Circulation. 110 (14): e340–437. PMID 15466654. Retrieved 2011-12-15. Unknown parameter
|month=ignored (help)